HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
HUTCHMED (China) LimitedNASDAQ: HCM
Revenue · Q2 FY2025 · quarter ended Jun 2025
Revenue declines year over year
Q2 FY2025 revenue of $138.84M fell 9.2% year over year, behind the -1.4% change in trailing-twelve-month revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 16 analysts of $631.45M (+14.8%) for the fiscal year ending Dec 2026, a step up from the -12.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- $138.84M+0.0% QoQ
- Last fiscal yearDec 2025
- $549.96M-12.7% YoY
- LTMJun 2025
- $602.2M-1.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.2% | -64.7% | -55.5 pp |
| 1 year | -12.7% | +14.8% | +27.5 pp |
| 3-year CAGR | +8.9% | +13.3% | +4.4 pp |
| 5-year CAGR | +19.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 549.96M USD
- Year-over-year change
- -12.7%
- 4-year CAGR
- +11.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 549.96M | -12.7% |
| FY2024 | 2024-12-31 | 630.2M | -24.8% |
| FY2023 | 2023-12-31 | 838M | +96.5% |
| FY2022 | 2022-12-31 | 426.41M | +19.7% |
| FY2021 | 2021-12-31 | 356.13M | — |
Revenue vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -1.4% is the 6th highest of 9, against a peer median of +7.2%.
- Over three fiscal years its annual growth of +8.9% compares with a peer median of +28.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $5.82B USD | +26.9% | +14.8% | |
| LTM Jun 2026 | $4.13B USD | — | -36.4% | |
| LTM Jun 2026 | €2.64B EUR | -8.2% | -45.8% | |
| LTM Jul 2026 | $2.44B USD | +9.2% | +12.9% | |
| LTM Sep 2026 | $1.36B USD | +49.5% | +106.4% | |
| LTM Jun 2025 | $602.2M USD | -1.4% | +8.9% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥558.48M CNY | -43.1% | +38.6% |
| LTM Jun 2026 | $449.61M USD | +5.1% | +28.9% | |
| LTM Mar 2026 | $225.27M USD | +3118.1% | +62.5% | |
| LTM Jun 2026 | $117M USD | -55.3% | +30.2% | |
| LTM Jun 2024 | $6.49M USD | — | — | |
| Peer median (excluding HCM) | — | +7.2% | +28.9% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.